Radiotherapy

News

Merck's Erbitux receives EC approval for head & neck cancer

Published December 1, 2008, 7:50 pm, PharmaBiz

Merck KGaA and its Merck Serono division announced that it has received approval from the European Commission to extend the use of its targeted therapy Erbitux (cetuximab) to include first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). Erbitux was previously approved for use in combination with radiotherapy for locally advanced ...

Full Story

Tags

No tags found at this time. Be the first to tag this news item, learn more.

Imagery

No related imagery found.

Related Radiotherapy Stories

From Various News Sources

No related news stories found.

Related Social Bookmarks

November 26th

Prophylactic cranial radiotherapy (PCR) : Cancerbackup

November 25th

Why won't our doctors face up to the dangers of radiotherapy? | Mail Online

November 20th

New accelerator enhances radiotherapy accuracy - physicsworld.c om

November 13th

Radiotherapy and Oncology

IAEA - Imaging in Radiotherapy

November 12th

Spezi and Lewis - An overview of Monte Carlo treatment planning for radiotherapy -- 131 (1): 123 -- Radiat Prot Dosimetry: Introductory article


News Directory

Get started fast by using a pre-defined news directory category

Breaking News
and Top Stories
Business
Earnings, Economy, Personal Finance, and Stock Markets
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss
Politics
Congress, Supreme Court, and White House
Science
Animals, Astronomy, Biotechnology, Space, and Weather
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis
Technology
Communications, Hardware, Internet, Personal Technology, and Software
United States
and Crimes and Trials
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East


© Copyright 2005-2006 News Meme, All Rights Reserved | More News | Link Index | OSWD Design

Powered by Odin Assemble 2.5a